- Home
- TNGX vs IMMR Comparison
TNGX vs IMMR Comparison
Compare TNGX & IMMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- IMMR
- Stock Information
- Founded
- TNGX 2014
- IMMR 1993
- Country
- TNGX United States
- IMMR United States
- Employees
- TNGX N/A
- IMMR N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- IMMR Computer peripheral equipment
- Sector
- TNGX Health Care
- IMMR Technology
- Exchange
- TNGX Nasdaq
- IMMR Nasdaq
- Market Cap
- TNGX 248.2M
- IMMR 236.5M
- IPO Year
- TNGX N/A
- IMMR 1999
- Fundamental
- Price
- TNGX $2.49
- IMMR $7.41
- Analyst Decision
- TNGX Strong Buy
- IMMR Strong Buy
- Analyst Count
- TNGX 6
- IMMR 2
- Target Price
- TNGX $12.20
- IMMR $12.25
- AVG Volume (30 Days)
- TNGX 3.5M
- IMMR 287.6K
- Earning Date
- TNGX 05-12-2025
- IMMR 06-10-2025
- Dividend Yield
- TNGX N/A
- IMMR 5.05%
- EPS Growth
- TNGX N/A
- IMMR 57.07
- EPS
- TNGX N/A
- IMMR 2.04
- Revenue
- TNGX $40,990,000.00
- IMMR $163,133,000.00
- Revenue This Year
- TNGX N/A
- IMMR $988.71
- Revenue Next Year
- TNGX N/A
- IMMR $109.72
- P/E Ratio
- TNGX N/A
- IMMR $3.68
- Revenue Growth
- TNGX 10.09
- IMMR 338.21
- 52 Week Low
- TNGX $1.03
- IMMR $6.47
- 52 Week High
- TNGX $12.02
- IMMR $13.94
- Technical
- Relative Strength Index (RSI)
- TNGX 62.72
- IMMR 49.22
- Support Level
- TNGX $1.93
- IMMR $7.24
- Resistance Level
- TNGX $2.67
- IMMR $7.67
- Average True Range (ATR)
- TNGX 0.39
- IMMR 0.16
- MACD
- TNGX 0.07
- IMMR 0.00
- Stochastic Oscillator
- TNGX 55.38
- IMMR 31.48
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About IMMR Immersion Corporation
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.